AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding AIM ImmunoTech Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 36 | 34 | −2 |
| Shares | 4.76M | 4.49M | −273.1K (−5.7%) |
| Value | $2.05M | $3.01M | +$959.0K (+46.8%) |
New holders (5)
Institutions that held AIM ImmunoTech Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 37,000 | $25.0K | 0.00% |
| Jane Street Group, LLC | 22,144 | $14.8K | 0.00% |
| D.B. Root & Company, LLC | 12,050 | $8.07K | 0.00% |
| GWM Advisors LLC | 1 | $1 | 0.00% |
| CWM, LLC | 1 | $0 | 0.00% |
Sold out (7)
Institutions that held AIM ImmunoTech Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Rockefeller Capital Management L.P. | 40,000 | $17.0K |
| Citadel Advisors LLC | 29,924 | $12.9K |
| Price T Rowe Associates Inc | 20,300 | $9.00K |
| Cambridge Investment Research Advisors, Inc. | 20,340 | $9.00K |
| Stephens Consulting, LLC | 1,500 | $645 |
| Creative Capital Management Investments LLC | 200 | $86 |
| New Millennium Group LLC | 33 | $14 |